Literature DB >> 962456

Reversal of intractable uremic pericarditis by triamcinolone hexacetonide.

T J Fuller, J P Knochel, J P Brennan, C D Fetner, M G White.   

Abstract

Of 74 patients undergoing long-term hemodialysis who were observed during a 21-month period, seven developed uremic pericarditis. Five of these patients developed intractable pericarditis, unresponsive to intensive dialysis and pericardiocentesis, and were treated with prolonged pericardial drainage (16 to 60 hours) by an indwelling polyethylene catheter and instillation of triamcinolone hexacetonide. Evidence of intractability was based on either the recurrence of cardiac tamponade after pericardiocentesis (two patients) or progression in the size of the pericardial effusion despite four weeks of intensive dialysis (three patients). These five patients recovered and subsequently were observed from 1 to 15 months with no evidence of recurrent pericarditis. This procedure may be an effective alternative to the surgical management of intractable uremic pericarditis, particularly in the patient at high risk for anesthesia and major surgery.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 962456

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  3 in total

1.  Cardiac tamponade without demonstrable pulsus paradoxus in haemodialysis patients.

Authors:  A J Watson; M M Finn; J A Keogh
Journal:  Ir J Med Sci       Date:  1981-03       Impact factor: 1.568

2.  Pericardioscopy and epi- and pericardial biopsy - a new window to the heart improving etiological diagnoses and permitting targeted intrapericardial therapy.

Authors:  Bernhard Maisch; Heinz Rupp; Arsen Ristic; Sabine Pankuweit
Journal:  Heart Fail Rev       Date:  2013-05       Impact factor: 4.214

3.  Intrapericardial triamcinolone hexacetonide in the treatment of intractable uremic pericarditis in a child.

Authors:  C R Medani; R E Ringel
Journal:  Pediatr Nephrol       Date:  1988-01       Impact factor: 3.714

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.